U.S., Dec. 18 -- ClinicalTrials.gov registry received information related to the study (NCT07287800) titled 'TRT as an Adjunctive ERAS Therapy in ESRD Patients Undergoing Kidney Transplantation' on Dec. 01.
Brief Summary: This prospective study aims to evaluate the safety and efficacy of testosterone replacement therapy (TRT) as an adjunct to an enhanced recover after surgery (ERAS) protocol in men with end-stage renal disease (ESRD) undergoing kidney transplantation.
Participants will be highly-listed hypogonadal men, defined as total testosterone level <300 on two occasions with clinical symptoms of hypogonadism, with ESRD who are expected to receive a kidney transplant within 6 months. Participants will be started on TRT, ideally for a...